中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
THE CHINESE JOURNAL OF CLINICAL PHARMACOLOGY
2014年
10期
907-908,918
,共3页
刘崇远%吕鲁闽%徐宝康
劉崇遠%呂魯閩%徐寶康
류숭원%려로민%서보강
转移性结直肠癌%卡培他滨%奥沙利铂%伊立替康
轉移性結直腸癌%卡培他濱%奧沙利鉑%伊立替康
전이성결직장암%잡배타빈%오사리박%이립체강
metastasis colorectal carcinoma%capecitabine%oxaliplatin%irinotecan
目的：评价卡培他滨（ CAP）联合奥沙利铂（ L -OHP）或伊立替康（CPT -11）治疗转移性结直肠癌的疗效及安全性。方法收治转移性结直肠癌患者66例，其中用 CAP ＋L -OHP 方案治疗者31例，CAP ＋CPT -11方案治疗者35例，2组均接受4周期化疗，分析2组患者临床有效率及化疗相关药物不良反应。结果CAP ＋L -OPH 组客观缓解率（ ORR）为19．4％， CAP ＋CPT -11组为20．0％，差别无统计学意义（P ＞0．05）；CAP ＋CPT -11组与 CAP ＋L -OHP 组整体Ⅲ～Ⅳ度不良反应发生率分别为51．6％和60．0％，差别无统计学意义（P ＞0．05），但 CAP ＋CPT -11组腹泻的发生率为22．9％，显著高于 L -OHP 组3．2％（ P ＜0．05）。结论CAP 联合L -OHP或 CPT -11治疗转移性结直肠癌临床疗效无明显差别，但CAP ＋CPT -11组严重腹泻发生率较高。
目的：評價卡培他濱（ CAP）聯閤奧沙利鉑（ L -OHP）或伊立替康（CPT -11）治療轉移性結直腸癌的療效及安全性。方法收治轉移性結直腸癌患者66例，其中用 CAP ＋L -OHP 方案治療者31例，CAP ＋CPT -11方案治療者35例，2組均接受4週期化療，分析2組患者臨床有效率及化療相關藥物不良反應。結果CAP ＋L -OPH 組客觀緩解率（ ORR）為19．4％， CAP ＋CPT -11組為20．0％，差彆無統計學意義（P ＞0．05）；CAP ＋CPT -11組與 CAP ＋L -OHP 組整體Ⅲ～Ⅳ度不良反應髮生率分彆為51．6％和60．0％，差彆無統計學意義（P ＞0．05），但 CAP ＋CPT -11組腹瀉的髮生率為22．9％，顯著高于 L -OHP 組3．2％（ P ＜0．05）。結論CAP 聯閤L -OHP或 CPT -11治療轉移性結直腸癌臨床療效無明顯差彆，但CAP ＋CPT -11組嚴重腹瀉髮生率較高。
목적：평개잡배타빈（ CAP）연합오사리박（ L -OHP）혹이립체강（CPT -11）치료전이성결직장암적료효급안전성。방법수치전이성결직장암환자66례，기중용 CAP ＋L -OHP 방안치료자31례，CAP ＋CPT -11방안치료자35례，2조균접수4주기화료，분석2조환자림상유효솔급화료상관약물불량반응。결과CAP ＋L -OPH 조객관완해솔（ ORR）위19．4％， CAP ＋CPT -11조위20．0％，차별무통계학의의（P ＞0．05）；CAP ＋CPT -11조여 CAP ＋L -OHP 조정체Ⅲ～Ⅳ도불량반응발생솔분별위51．6％화60．0％，차별무통계학의의（P ＞0．05），단 CAP ＋CPT -11조복사적발생솔위22．9％，현저고우 L -OHP 조3．2％（ P ＜0．05）。결론CAP 연합L -OHP혹 CPT -11치료전이성결직장암림상료효무명현차별，단CAP ＋CPT -11조엄중복사발생솔교고。
Objective To evaluate the efficacy and safety of oxaliplatin (L -OHP) or irinotecan ( CPT -11 ) combined with capecitabine (CAP) in the treatment of metastasis colorectal carcinoma.Methods Sixty -six patients with metastasis colorectal carcinoma were recruited in this study.There were 31 cases in CAP plus L -OHP group and 35 sub-jects in CAP plus CPT -11 group.All of the included cases were treated with 4 cycles of chemotherapy.The clinical efficacy and chemotherapy related side effects were compared between the two groups .Results The objective response rate (ORR) were 19.4% and 20.0% in the CAP plus L -OHP and CAP plus CPT -11 group respectively without statistical difference (P >0.05).The grade Ⅲ to Ⅳ adverse reactions in the CAP plus CPT -11 group and CAP plus L -OHP group were 51.6% and 60.0%, without statistical differences in two groups (P >0.05) .But diarrhea incidence in the CAP plus CPT -11 group (22.9%) was much higher than that in the CAP plus L -OHP group (3.2%) (P <0.05). Conclusion There was no statistical difference on clinical efficacy between the two chemotherapy regimens, but there is a higher incidence of serious diarrhea in CAP plus CPT -11 regimen.
